Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announces that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK (LSE/NYSE: GSK). This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site, a significant expansion of the company’s global footprint and its long-term commitment to the U.S. market. Located in Rockville, Maryland, the facility sits at the center of one of the key U.S. bio-clusters and encompasses two cGMP manufacturing plants with a combined 60,000 liters of drug substance capacity.
Read the full article: Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK //
Source: https://www.prnewswire.com/news-releases/samsung-biologics-expands-us-manufacturing-capabilities-with-strategic-acquisition-of-human-genome-sciences-from-gsk-302647637.html